A Phase 1b/2 Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of the Selective SYK Inhibitor Lanraplenib (LANRA) in Combination with the FLT3 Inhibitor Gilteritinib, in Patients with FLT3-Mutated Relapsed or Refractory AML

This multicenter, Phase 1b/2 study will investigate the safety, PK, PD and make a
preliminary assessment of the anti-leukemic activity of the selective, 3rd generation SYK
inhibitor, LANRA, in combination with the selective FLT3 inhibitor, gilteritinib, in patients
with FLT3-mutated AML, who have recurrence of leukemia or are refractory after at least 1
prior regimen. This study will be conducted in 2 parts: dose escalation (Phase 1b) and cohort
expansion (Phase 2).